POSA28 Reductions in Migraine and Headache Days After Initiating Fremanezumab for Patients with Migraine and Prior Use of Another Monoclonal Antibody Targeting the CGRP Pathway in a US Real-World Setting
Jan 1, 2022, 00:00
10.1016/j.jval.2021.11.101
https://www.valueinhealthjournal.com/article/S1098-3015(21)01896-9/fulltext
Title :
POSA28 Reductions in Migraine and Headache Days After Initiating Fremanezumab for Patients with Migraine and Prior Use of Another Monoclonal Antibody Targeting the CGRP Pathway in a US Real-World Setting
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)01896-9&doi=10.1016/j.jval.2021.11.101
First page :
Section Title :
Open access? :
No
Section Order :
10659